Nov 13, 2023 8:01am EST Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Nov 02, 2023 7:01am EDT Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
Sep 07, 2023 8:01am EDT Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Sep 05, 2023 8:01am EDT Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 7:01am EDT Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Aug 07, 2023 7:01am EDT Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Jul 10, 2023 8:00am EDT Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
Jul 05, 2023 4:15pm EDT Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 29, 2023 8:00pm EDT Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 06, 2023 7:35am EDT Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
